NCT07052695 - Mosunetuzumab for CLL MRD Clearance | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

July 1, 2032

Conditions

LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLymphoma

Interventions

DRUG

Mosunetuzumab

Subcutaneous injection of a CD20xCD3 bispecific antibody

DRUG

Ibrutinib

For participants who have been ibrutinib PO prior to enrollment

DRUG

Acalabrutinib

For participants who have been acalabrutinib PO prior to enrollment

DRUG

Zanubrutinib

For participants who have been zanubrutinib PO prior to enrollment

DRUG

Pirtobrutinib

For participants who have been pirtobrutinib PO prior to enrollment

Trial Locations (2)

Brigham & Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston